Author:
Agnelli G.,Eriksson B.I.,Cohen A.T.,Bergqvist D.,Dahl O.E.,Lassen M.R.,Mouret P.,Rosencher N.,Andersson M.,Bylock A.,Jensen E.,Boberg B.
Reference15 articles.
1. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects;Gustafsson;Thromb Res,2001
2. Single and repeated oral dosing of H 376/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects;Eriksson;Blood,1999
3. A comparison of the pharmacokinetics of ximelagatran (pINN, formerly H 376/95) in young and elderly heALAThy subjects;Johansson;Thromb Haemost,2001
4. The pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism;Eriksson;Thromb Haemost,2001
5. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial;Eriksson;Lancet,2002
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献